The STAR (Sigrid Therapeutics HbA1c Reduction) study is an open-label, single-arm, multicentre study with the objective of demonstrating the safety and efficacy of SiPore15™ in subjects with prediabetes or newly diagnosed type 2 diabetes. The goal of the clinical trial is to demonstrate an improvement in cardio-metabolic risk factors in the target population. The results from this study will guide further clinical development of SiPore15™.
To read more about the clinical trial STAR, click below.
Interested in participating?
We are currently recruiting patients for the STAR study at research clinics in Finland and Sweden.
Contact details: Nurse Gabriella Seger
Contact details: Nurse Laura Jääskeläinen
Phone: +358 40 774 1104
”SiPore15™ represents an entirely new approach to reducing blood sugar levels and other cardio-metabolic risk factors. The excellent safety profile of the device makes it especially suitable for people at risk of developing type 2 diabetes. We are excited for the STAR study and anticipate the device to show robust safety data and clinically significant results as seen in previous clinical trials with the device.Professor, MD, Kirsi PietiläinenLeading obesity expert & Coordinating Investigator STAR